Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management

The objective of this report is to provide guidance on the prophylaxis, monitoring, and management of adverse events (AEs) in patients with breast cancer treated with T-DXd, and to emphasize that proper management of AEs is needed to optimize the effectiveness of T-DXd treatment and reduce the number of discontinuations. The article covers various aspects of T-DXd treatment, including its clinical efficacy, safety profile, and dos ing considerations, and provides practical recommendations for managing AEs, such as nausea/vomiting, interstitial lung disease, and hematologic toxicity. Although there are still many knowledge gaps about the cause and incidence of AEs in real-world patients, this document may serve as a valuable r esource for clinicians who are involved in the care of breast cancer patients receiving T-DXd treatment.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research